• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Teleflex receives FDA 510(k) Clearance for Expanded Indications of the QuikClot Control+™ Hemostatic Device

    4/30/25 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care
    Get the next $TFX alert in real time by email

    WAYNE, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of an expansion to the Indications for Use of the QuikClot Control+™ Hemostatic Device to include all grades of internal and external bleeding. The QuikClot Control+™ Device was previously indicated for temporary control of class III and class IV internal organ space bleeding, severely bleeding surgical wounds, mild and moderate bleeding in cardiac surgical procedures, and bone surfaces following sternotomy.

    "Bleeding remains a major contributor to mortality and morbidity in the United States," said Kevin Robinson, President and General Manager, Anesthesia and Emergency Medicine, Teleflex. "Uncontrolled, disruptive bleeding can significantly impact the clinical and economic outcomes of surgery.1 The expanded indication for the QuikClot Control+™ Device portfolio allows us to target more procedures where fast, effective control of bleeding could benefit patients, clinicians, and health systems. Our primary focus remains on trauma, but this expanded indication will also support procedures in general surgery, gynecologic surgery, orthopedic surgery, and other areas. We estimate that these additional clinical spaces add more than $150 million to our serviceable addressable market in the United States.2"

    To support the labeling change, Teleflex used real-world evidence (RWE) from a retrospective, statistically powered, observational study of 603 emergency, trauma, and surgical patients. The study assessed the effectiveness and safety of the QuikClot Control+™ Device to control all grades of bleeding in multiple and varied anatomical sites during surgical procedures and in bleeding due to injuries. The RWE, representing a broad patient population from multiple sites across the U.S., led to the FDA clearance of the expanded indications.

    "Real-world evidence was leveraged by Teleflex to obtain FDA clearance for this clinically important, expanded indication," said Michelle Fox, Corporate Vice President and Chief Medical Officer, Teleflex. "This means we are able to bring the technology of the QuikClot Control+™ Device portfolio to more clinicians who will benefit from its ability to provide improved bleeding control for all grades of bleeding, from surgery to resuscitation." 

    The QuikClot Control+™ Hemostatic Device is now indicated for temporary control of external and identifiable sites of internal mild, moderate, severe, and life-threatening bleeding in the United States.

    The QuikClot Control+™ Hemostatic Device is indicated for temporary control of internal and external mild, moderate, severe, and traumatic bleeding due to injuries and/or surgical wounds in the European Union (EU) and was commercialized in the EU in 2024.

    About Teleflex Incorporated

    As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

    Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

    At Teleflex, we are empowering the future of healthcare. For more information, please visit www.teleflex.com.

    Forward-Looking Statements

    Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties, and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

    Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, QuikClot Control+, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

    © 2025 Teleflex Incorporated. All rights reserved. MC-010730

    References:

    1. Johnston, SS, Afolabi, M, Tewari, R, Danker, W. ClinicoEconomics and Outcomes Research. 2023;15:535-547.
    2. Internal estimate.

    Contacts:

    Teleflex

    Lawrence Keusch

    Vice President, Investor Relations and Strategy Development

    [email protected]

    610-948-2836



    Primary Logo

    Get the next $TFX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TFX

    DatePrice TargetRatingAnalyst
    3/4/2025$235.00 → $140.00Neutral → Underperform
    BofA Securities
    2/28/2025$220.00 → $155.00Outperform → Sector Perform
    RBC Capital Mkts
    2/28/2025Outperform → Mkt Perform
    Raymond James
    2/28/2025$255.00 → $140.00Overweight → Neutral
    Piper Sandler
    2/27/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    7/1/2024$205.00 → $245.00Neutral → Overweight
    Piper Sandler
    12/4/2023$261.00Equal-Weight → Overweight
    Morgan Stanley
    6/21/2023Buy → Hold
    Needham
    More analyst ratings

    $TFX
    SEC Filings

    See more
    • SEC Form 11-K filed by Teleflex Incorporated

      11-K - TELEFLEX INC (0000096943) (Filer)

      6/27/25 2:33:24 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Teleflex Incorporated

      SD - TELEFLEX INC (0000096943) (Filer)

      5/29/25 10:58:02 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Incorporated filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - TELEFLEX INC (0000096943) (Filer)

      5/15/25 4:06:35 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Teleflex downgraded by BofA Securities with a new price target

      BofA Securities downgraded Teleflex from Neutral to Underperform and set a new price target of $140.00 from $235.00 previously

      3/4/25 7:44:32 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Teleflex from Outperform to Sector Perform and set a new price target of $155.00 from $220.00 previously

      2/28/25 7:34:55 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex downgraded by Raymond James

      Raymond James downgraded Teleflex from Outperform to Mkt Perform

      2/28/25 7:34:03 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Duncan Candace H was granted 1,051 shares, increasing direct ownership by 22% to 5,907 units (SEC Form 4)

      4 - TELEFLEX INC (0000096943) (Issuer)

      5/13/25 5:03:30 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Director Patil Neena M was granted 1,051 shares, increasing direct ownership by 67% to 2,626 units (SEC Form 4)

      4 - TELEFLEX INC (0000096943) (Issuer)

      5/13/25 5:03:06 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Director Heinmiller John C was granted 1,051 shares, increasing direct ownership by 34% to 4,176 units (SEC Form 4)

      4 - TELEFLEX INC (0000096943) (Issuer)

      5/13/25 5:03:20 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Teleflex Completes Acquisition of BIOTRONIK's Vascular Intervention Business

      WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex's portfolio of interventional access products, driving an enhanced global presence in the cath lab. The Vascular Intervention business will also establish Teleflex's global footprint in the fast-growing peripheral intervention market, and provide a channel for Teleflex products that currently have a peripheral indication. On Febr

      7/1/25 6:30:13 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients

      WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt and Turkey. Key highlights include: The pre-specified CVC subgroup analysis evaluated the impact of Chlorhexidine-impregnated CVCs on CLABSI rates using CLABSI rates per 1,000 CL (central-line)-days.70.5% reduction in the incidence of CLABSI in patien

      6/12/25 6:29:59 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men's Health Month

      Timed with National Men's Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health. The Teleflex Prostate Education Express, a mobile training and education center, is on a national tour to educate physicians and the community on prostate health quality-of-life issues associated with BPH and the importance of organ spacing to protect against potential rectal side effects in advance of prostate cancer radiation treatment.   WAYNE, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading globa

      6/11/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Leadership Updates

    Live Leadership Updates

    See more
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance
    • Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

      Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

      3/4/25 11:38:00 AM ET
      $ABT
      $TFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Teleflex Announces Planned Retirement of Thomas Powell As Chief Financial Officer

      WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that Thomas E. Powell, Teleflex's Chief Financial Officer, has decided to retire as Executive Vice President and Chief Financial Officer, effective April 1, 2025. John R. Deren, who currently serves as Corporate Vice President and Chief Accounting Officer of Teleflex, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2, 2025. Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition. "Tom has announced his des

      2/27/25 6:36:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Financials

    Live finance-specific insights

    See more
    • Teleflex Completes Acquisition of BIOTRONIK's Vascular Intervention Business

      WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex's portfolio of interventional access products, driving an enhanced global presence in the cath lab. The Vascular Intervention business will also establish Teleflex's global footprint in the fast-growing peripheral intervention market, and provide a channel for Teleflex products that currently have a peripheral indication. On Febr

      7/1/25 6:30:13 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Announces Quarterly Dividend

      WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 16, 2025, to shareholders of record at the close of business on May 20, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgi

      5/12/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook

      WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $700.7 million, down 5.0% compared to the prior year period; down 3.8% on an adjusted constant currency basis GAAP diluted EPS from continuing operations of $2.07, compared to $0.33 in the prior year period Adjusted diluted EPS from continuing operations of $2.91, compared to $3.21 in the prior year period 2025 guidance summary Raising GAAP revenue growth guidance range to 1.28% to 2.28% Maintaining adjusted constant currency revenue growth guidan

      5/1/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $TFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

      SC 13G/A - TELEFLEX INC (0000096943) (Subject)

      11/14/24 1:28:29 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

      SC 13G/A - TELEFLEX INC (0000096943) (Subject)

      11/8/24 10:29:30 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Teleflex Incorporated (Amendment)

      SC 13G/A - TELEFLEX INC (0000096943) (Subject)

      2/14/24 10:04:36 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care